1. Background {#sec212658}
=============

Neutropenia is defined as a reduction in blood neutrophil counts to less than 1500/mm^3^ ([@A41446R1]). This disease is the most common condition in patients with hematological malignancy ([@A41446R2]), cytostatic chemotherapy ([@A41446R3]), hematopoietic stem cell transplantation ([@A41446R4]) and acute leukemia ([@A41446R5]). This condition is one of the most important risk factors for several fungal invasive infections (such as, invasive candidiasis and aspergillosis). As a result, such infections could be associated with high morbidity and mortality, and increase the duration of hospitalization in neutropenic patients ([@A41446R6]). Generally, the incidence of systemic mycosis has increased dramatically over the past 30 to 40 years due to new invasive therapies.

*Candida* and *Aspergillus* species are the two most important fungal agents that are responsible for several fungal infections among neutropenic patients ([@A41446R3]). Although, *Candida albicans* is the most common infectious agent among neutropenic patients, however, there has been an increasing rate of non-albicans species (*C. krusei*, *C. glabrata* and *C. tropicalis*) in the recent years. In addition, extensive antifungals prophylaxis (Amphotericin B and fluconazole) during/after chemotherapy increased the resistance to some isolates of *Candida* species especially non-*albicans* strains ([@A41446R7]). Although, several host predisposing factors influence the pathogenicity of agents, extracellular enzymes have an important role in the pathogenesis. The role of phospholipase, esterase, proteinase and haemolysin, in the pathogenicity of *Candida* species, has been well documented ([@A41446R8]). On the other hand, the extracellular enzymatic profile differs between different recovered isolates from different clinical samples.

Amphotericin B, fluconazole and itraconazole are routinely used for chemotherapy and chemoprophylaxis in neutropenic patients ([@A41446R7], [@A41446R9], [@A41446R10]). Recently, caspofungin (blocker β-1,3-D glucan synthase enzyme) has been introduced as an effective antifungal against systemic candidiasis in neutropenic patients ([@A41446R2]). On the other hand, nystatin mouthwash solutions are also used for the treatment of oral lesions. Therefore, in vitro assay of antifungal drugs against *Candida* species could be useful for best management and treatment by clinicians.

2. Objectives {#sec212659}
=============

The aim of the present study was to detect *Candida* species from hospitalized neutropenic patients at Shafa hospital in Ahvaz. In addition, antifungal susceptibility profiles in causative agents and the pattern of extracellular enzymes activity were also evaluated.

3. Patients and Methods {#sec212665}
=======================

3.1. Patients and Sampling {#sec212660}
--------------------------

This descriptive study was approved by the ethical committee of Ahvaz Jundishapur University of Medical Sciences (ajums.REC.1393.150). All patients or parents signed a consent form before sampling. In the present study, 243 hospitalised neutropenic patients (neutrophil count less than 1500 neutrophils per microliter) at Shafa hospital, affiliated to Ahvaz Jundishapur University of Medical Sciences, were sampled. All patients were under prophylactic treatment with fluconazole or amphotericin B. Different specimens including 100 blood samples, 243 urine samples and 243 swabs from oral cavity of patients were collected. Swabs from oral cavity and 10 µL of urine samples were cultured on CHROMagar Candida plates (CHROMagar Candida, France) and incubated at 37°C for 48 - 72 hours. In addition, 2 mL of blood samples were inoculated into biphasic brain heart infusion (BHI, Baharafshan, Iran) bottles and incubated at 37°C for seven days. Bottles were aerated using a sterile syringe needle every day.

3.2. Classical Identification {#sec212661}
-----------------------------

All isolated yeasts species were identified using routine mycological tests, such as germ tube formation on human serum, microscopy morphology on cornmeal agar (High Media, India) plus 1% Tween 80 (Merck, Germany), growth at 42 - 45°C and colony morphology on CHROMagar Candida.

3.3. DNA Extraction, Amplification and Sequencing {#sec212662}
-------------------------------------------------

In the present study, 40 strains (all non-albicans species, nine strains of *C. krusei* and five strains of *C. albicans*) were subjected for polymerase chain reaction (PCR) analysis. Yeasts were cultured on sabouraud dextrose agar (SDA, Merck, Germany) and incubated at 37°C overnight. A small amount of each yeast colony was collected in special cryotube vials containing 300 µL of lysis buffer and 30 mg glass bed. Yeasts were homogenized with SpeedMill Plus system (Analytik Jena, Germany) for two minutes and then incubated at 100°C for two minutes. Overall, 150 µL of 3 M Sodium acetate was added to each tube and kept at -20°C for 10 minutes. Tubes were centrifuged at 12000 rpm for 10 minutes at 4°C and then supernatants were separated and extracted using phenol-chloroform-isoamyl alcohol ([@A41446R11]).

All extracted DNA were kept at -20°C until use. The internal transcribed spacer (ITS) region of the rDNA was amplified by PCR with the primers V9G (5'-TTACGTCCCTGCCCTTTGTA-3') and LS266 (5'-GCATTCCCAAACAACTCGACTC-3') ([@A41446R12]). The PCR products were sequenced by the Bioneer company (Bioneer, Daejeon, South Korea). The results of DNA sequencing were analyzed using the Chromas Lite program (Technelysium, Version 2.4) and similarity to the sequenced genes in GenBank library was evaluated.

3.4. Enzymatic Activities {#sec212663}
-------------------------

The activity of extracellular enzymes (phospholipase, esterase, proteinase and haemolysin) of isolated strains was detected by several specific tests that were previously used by our team ([@A41446R13]-[@A41446R15]). Briefly, phospholipase activity was assessed by SDA supplemented with egg yolk. Bovine serum albumin agar medium (Merck, Germany) and Tween 80 (Merck, Germany) opacity test medium were used for the assessment of proteinase and esterase activities, respectively. sabouraud dextrose agar supplement with 3% glucose (Merck, Germany) and 7% defibrinated sheep blood was used for the detection of haemolytic activity. Finally, the extracellular enzymes indexes were calculated according to Price et al. ([@A41446R16])

3.5. Susceptibility Tests {#sec212664}
-------------------------

In the present study, 95 yeast isolates including; *C. albicans* (50 isolates), *C. krusei* (20), *C. glabrata* (7), *C. tropicalis* (4), *C. kefyr* (3), *C. dubliniensis* (5), *C. parapsilosis* (2), *C. orthopsilosis* (1), *C. lambica* (1), *C. hellenica* (1) and *Saccharomyces cerevisiae*(1) were tested against amphotericin B, fluconazole and caspofungin in vitro using modified Clinical and laboratory standards institute (CLSI) method. A stock solution of 1.25 mg/mL for caspofungin (Sigma - Aldrich, Germany) and 32 mg/mL for amphotericin B (Sigma - Aldrich, Germany) and fluconazole (Serva, USA) were prepared in dimethyl sulfoxide (DMSO, Fluka, Germany). Antifungal stocks were kept at -20 until use. A serial dilution of each antifungal was prepared in RPMI (Bio Idea, Iran) containing 0.01% Alamar Blue (Resazurin) (Sigma - Aldrich, Germany) ([@A41446R17]-[@A41446R19]).

A serial dilution of caspofungin was prepared from 4 - 0.03125 µg/mL. In addition, serial dilution of each amphotericin B and fluconazole was separately prepared from 32 to 0.25 µg/mL. Then, 100 µL of antifungal and 100 µL of diluted standard yeast suspension were added to each microplate well. Microplates were incubated at 35°C for 24 to 48 hours, aerobically. Positive and negative controls contained, medium and suspension, and antifungal drug, respectively. The last unchanged blue color microplate well to red color was recorded as minimum inhibitory concentration (MIC) for each tested yeast against each antifungal drug ([Figure 1](#fig39018){ref-type="fig"}).

![Resazurin Dye Test for Determining Minumum Inhibitory Concentration of Fluconazole and Caspofungin to Candida Species](jjm-09-11-41446-g001){#fig39018}

4. Results {#sec212669}
==========

4.1. Patients and Organisms {#sec212666}
---------------------------

We examined 243 neutropenic patients (54.3% female and 45.7% male) with age range from \>5 to 75 years. Fifteen (6.2%) cases of 243 sampled patients had candiduria, 12 cases were females and 3 cases were males. On the other hand, oral swabs from 95 cases yielded different yeast species. Our results showed that 110 different yeast species were isolated including; 109 (99.1%) *Candida* species and one (0.9%) non-*Candida* yeast. The most common species was *C. albicans* (57), followed by *C. krusei* (28), *C. glabrata* (7), *C. tropicalis* (4), *C. kefyr* (3), *C. dubliniensis* (5), *C. parapsilosis* (2), *C. orthopsilosis* (1), *C. lambica* (1), *C. hellenica* (1), and *S. Cerevisiae* (1) ([Table 1](#tbl53582){ref-type="table"}). In the present study, we couldn't recover any yeast from blood samples using biphasic BHI.

###### Recovered Yeast Species From Oral Cavity and Urine Samples of Neutropenic Patients

  Yeasts Species          Oral Cavity, No. (%)   Urine, No. (%)   Total, No. (%)
  ----------------------- ---------------------- ---------------- ----------------
  ***C.albicans***        50 (45.5)              7 (6.4)          57 (51.8)
  ***C.krusei***          23 (20.9)              5 (4.5)          28 (25.5)
  ***C.glabrata***        5 (4.5)                2 (1.8)          7 (6.4)
  ***C.dubliniensis***    4 (3.6)                1 (0.9)          5 (4.5)
  ***C.tropicalis***      4 (3.6)                0 (0.0)          4 (3.6)
  ***C.kefyr***           3 (2.7)                0 (0.0)          3 (2.7)
  ***C.parapsilosis***    2 (1.8)                0 (0.0)          2 (1.8)
  ***C.lambica***         1 (0.9)                0 (0.0)          1 (0.9)
  ***C.orthopsilosis***   1 (0.9)                0 (0.0)          1 (0.9)
  ***C.hellenica***       1 (0.9)                0 (0.0)          1 (0.9)
  ***S.cerevisiae***      1 (0.9)                0 (0.0)          1 (0.9)
  **Total**               95 (86.4)              15 (13.6)        110 (100)

4.2. Extracellular Enzymes {#sec212667}
--------------------------

[Table 2](#tbl53583){ref-type="table"} summarizes the details of extracellular enzymes production in different species of *Candida*. The haemolytic and proteinase activities of oral isolates of *Candida* were observed to be much higher than urinary isolates. However, urinary strains showed higher esterase activity than oral species.

###### Extracellular Enzymes Activity of Isolated Yeasts

  Hi Value          Haemolytic Activity      Oral Isolates, No. (%)   Urine Isolates, No. (%)   Total, No. (%)
  ----------------- ------------------------ ------------------------ ------------------------- ----------------
  **1**             Negative                 8 (8.4)                  1 (6.7)                   9 (8.2)
  **0.70 - 0.99**   Low (1+)                 11 (11.5)                11 (73.3)                 22 (20)
  **0.40 - 0.69**   Medium (2+)              17 (17.9)                1 (6.7)                   18 (16.4)
  **0.10 - 0.39**   High (3+)                59 (62.1)                2 (13.3)                  61 (55.4)
  **Total**                                  95 (100)                 15 (100)                  110 (100)
  **Ez Value**      Esterase activity                                                           
  **1**             Negative                 5 (5.3)                  1 (6.7)                   6 (5.4)
  **0.70 - 0.99**   Low (1+)                 25 (26.3)                4 (26.6)                  29 (26.4)
  **0.40 - 0.69**   Medium (2+)              50 (52.6)                2 (13.3)                  52 (47.3)
  **0.10 - 0.39**   High (3+)                15 (42.8)                8 (53.3)                  23 (20.9)
  **Total**                                  95 (100)                 15 (100)                  110 (100)
  **Pz Value**      Phospholipase activity                                                      
  **1**             Negative                 4 (4.2)                  3 (20)                    7 (6.4)
  **0.70 - 0.99**   Low (1+)                 17 (17.9)                2 (13.3)                  19 (17.3)
  **0.40 - 0.69**   Medium (2+)              43 (45.3)                6 (40)                    49 (44.5)
  **0.10 - 0.39**   High (3+)                31 (32.6)                4 (26.6)                  35 (31.8)
  **Total**                                  95 (100)                 15 (100)                  110 (100)
  **Pz Value**      Proteinase activity                                                         
  **1**             Negative                 2 (2.1)                  0 (0)                     2 (1.8)
  **0.70 - 0.99**   Low (1+)                 32 (33.7)                3 (20)                    35 (31.8)
  **0.40 - 0.69**   Medium (2+)              23 (24.2)                7 (46.7)                  30 (27.3)
  **0.10 - 0.39**   High (3+)                38 (40)                  5 (33.3)                  43 (39.1)
  **Total**                                  95 (100)                 15 (100)                  110 (100)

4.3. Antifungal Susceptibility {#sec212668}
------------------------------

In the present study, 94 isolates of *Candida* species and one *Saccharomyces cerevisiae* were tested against three antifungal drugs including; amphotericin B, fluconazole and caspofungin. After 24 and 48 hours, 54.7% and 72.6% of the isolates were resistant to amphotericin B (\< 8 µg/mL), respectively. Amphotericin B resistance was found after 24 to 48 hours of incubation in 57.1%, of *C. glabrata* isolates. However, drug resistance among the isolates of *C. krusei* increased from 50% to 65% when incubation period was extended to 48 hours. Fluconazole was shown to have good efficacy against all tested isolates, and dose dependent sensitivity to fluconazole (≤ 16 µg/mL) was only identified in one isolate of *C. krusei* after 48 hours of incubation. During this study, it was found that all of tested isolates were sensitive to caspofungin at a range of 2 - \> 0.03125 µg/mL. [Table 3](#tbl53584){ref-type="table"} summarizes the results of MIC ranges, MIC50, MIC90 and geometric mean MIC. Overall, for all isolates, MICs 50%, 0.5 µg/mL was increased to 1 µg/mL after 48 hours, when MICs 90% was fixed 2 µg/mL after 24 and 48 hours incubation for caspofungin.

###### The Antifungal Susceptibility of Isolates to Amphotericin B, Fluconazole and Caspofungin

  Antifungal Agents                           Minimum Inhibitory Concentration, µg/mL                
  ------------------------------------------- ----------------------------------------- ------- ---- ----------
  ***Candida albicans***, **n = 50**                                                                 
  Amphotericin B                              16 - ≥ 0.125                              16      16   13.52224
  Fluconazole                                 2 - 0.125                                 0.5     1    0.59874
  Caspofungin                                 2 - \> 0.03125                            0.5     1    0.46652
  ***Candidaglabrata*** **, n = 7**                                                                  
  Amphotericin B                              16 - ≥ 0.125                              16      16   9.68625
  Fluconazole                                 4 - 0.125                                 0.125   2    0.41017
  Caspofungin                                 2 - \> 0.03125                            1       2    0.3715
  ***Candidatropicalis*** **, n = 4**                                                                
  Amphotericin B                              16 - 8                                    16      16   13.45434
  Fluconazole                                 2 - 0.25                                  1       2    1
  Caspofungin                                 2 - 0.25                                  1       2    0.8409
  ***Candidakrusei*** **, n = 20**                                                                   
  Amphotericin B                              16 - ≥ 0.125                              8       16   3.605
  Fluconazole                                 16 - 0.125                                0.25    4    0.46652
  Caspofungin                                 2 - \> 0.03125                            0.25    1    0.19615
  ***Candidadubliniensis*** **, n = 5**                                                              
  Amphotericin B                              16 - 4                                    8       16   8
  Fluconazole                                 8 - 0.125                                 1       8    1
  Caspofungin                                 2 - \> 0.25                               1       2    1
  ***Saccharomycescerevisiae*** **, n = 1**                                                          
  Amphotericin B                              16                                        \-      \-   \-
  Fluconazole                                 2                                         \-      \-   \-
  Caspofungin                                 2                                         \-      \-   \-
  **Candida kefyr, n = 3**                                                                           
  Amphotericin B                              16                                        \-      \-   \-
  Fluconazole                                 16 - 0.125                                \-      \-   \-
  Caspofungin                                 2 - \>0.5                                 \-      \-   \-
  ***Candidalambica*** **, n = 1**                                                                   
  Amphotericin B                              16                                        \-      \-   \-
  Fluconazole                                 1                                         \-      \-   \-
  Caspofungin                                 0.25                                      \-      \-   \-
  ***Candidahellenica*** **(n = 1**                                                                  
  Amphotericin B                              8                                         \-      \-   \-
  Fluconazole                                 1                                         \-      \-   \-
  Caspofungin                                 0.25                                      \-      \-   \-
  ***Candidaorthopsilosis*** **, n = 1**                                                             
  Amphotericin B                              4                                         \-      \-   \-
  Fluconazole                                 0.5                                       \-      \-   \-
  Caspofungin                                 1                                         \-      \-   \-
  ***Candidaparapsilosis*** **, n = 2**                                                              
  Amphotericin B                              8 - 4                                     \-      \-   \-
  Fluconazole                                 8 - 4                                     \-      \-   \-
  Caspofungin                                 0.0625 - \> 0.03125                       \-      \-   \-
  **All isolated yeasts, n = 95**                                                                    
  Amphotericin B                              16 - ≥ 0.125                              16      16   6.28813
  Fluconazole                                 16 - ≥ 0.125                              0.5     2    0.64078
  **Caspofungin**                             2 - \>0.03125                             0.5     2    0.40465

5. Discussion {#sec212670}
=============

Since neutropenic patients are usually at high risk for invasive candidiasis, colonization of mucosal tissues with *Candida* species is more important for them. In this condition, transaction of *Candida* species via mucosal tissues into bloodstream causes candidemia. Indeed, some authors believe that candiduria among neutropenic patients could be evaluated as a marker for systemic candidiasis and suitable antifungals drugs must be prescribed ([@A41446R20], [@A41446R21]). In the present study, we investigated the epidemiological features of *Candida* colonization among hospitalized neu-tropenic patients. Our results showed that the urinary system in 6.2% of cases (12 females and 3 males) was colonized with different species of *Candida* (Candiduria), whereas oral cavity in 95 (39.1%) (females 27, 28.5% and males 68, 71.6 %) of the patients was colonized with different species of *Candida* and non-*Candida* species. Similar reports showed a difference in the colonization of *Candida* among neutropenic patients, for example colonization was indicated in 46.8% of pediatric patients with neutropenia ([@A41446R22]), 66% of patients undergoing hematopoietic stem-cell transplantation ([@A41446R3]) and 61.8% of neutropenic very low-birth-weight neonates ([@A41446R23]). In addition, Zollner-Schwetz et al., believed that gastrointestinal tract colonization by *Candida* species in neutropenic patients is an important risk factor for invasive candidiasis. They also found that 48% of multi-colonized patients had same *Candida* species in their oral and intestinal samples ([@A41446R24]).

Although, *C. albicans* is the first most common candidiasis agent and human colonizer, increasing non-albicans species such as *C. glabrata*, *C. krusei*, *C. parapsilosis* and *C. tropicalis* have been reported by several researchers during the last decades ([@A41446R25]-[@A41446R27]). In a study by Betts et al. ([@A41446R9]) *C. tropicalis* (37%) was accounted as the major invasive candidiasis agent in neutropenic patients, followed by *C. albicans* (22%) and *C. krusei* (11%). The authors revealed that neutropenic patients were mainly colonized with *C. albicans* (51.8%) followed by non-albicans species of *C. krusei* (25.5%). On the other hand, very rare species of *Candida*, such as C*. hellenica* ([@A41446R28]) and *C. lambica* ([@A41446R29]), were reported as human pathogens. *Candida lambica*, *C. hellenica*, *C. orthopsilosis* and *S. cerevisiae* were rare non-albicans species that were recovered from our patients.

Nosocomial infections, candidemia and candiduria, by non-*albicans* species have considerably increased during the last decades. Moreover, virulence factors, such as phospholipase, esterase, proteinase and haemolysin have been well documented among vaginal and urine isolates of *Candida* ([@A41446R13]-[@A41446R15], [@A41446R30]). Furthermore, host tissue colonization and tissue invasion have been associated with extracellular enzymes production by isolates. On the hand, little information is available concerning the role of extracellular enzymes in the colonization of *Candida* in neutropenic patients. A few isolates were phospholipase and protease positive in the study of Negri et al., ([@A41446R31]), whereas in contrast, 100% and 72.9% of *Candida*species from pulmonary tuberculosis patients produced proteases and phospholipase as reported by Kumar et al. ([@A41446R32]). More researchers believe that the virulence in *C. albicans* is correlated with the combination of several factors including, high phospholipase activity and germ tube production ([@A41446R33]). Our study showed that only a few isolates were negative for the production of extracellular enzymes and the enzymatic activity of 90% of isolates were at medium (2+) and high (3+) ranges ([Table 2](#tbl53583){ref-type="table"}).

Fluconazole, a triazole antifungal, is active against *Candida* species in neutropenic patients ([@A41446R34]) as well as other infections. Furthermore, drugs are used as first line therapy for esophageal candidiasis among neutropenic patients ([@A41446R2]). On the other hand, both fluconazole and amphotericin B are widely used for prophylaxis in neutropenic patients ([@A41446R7]). Reports indicated that the sensitivity of *C. glabrata*, *C. krusei* and *C. tropicalis* was decreased to fluconazole and amphotericin B during several past decades ([@A41446R35]-[@A41446R40]). The frequency of fluconazole resistance was 20.3% among several species of *Candida* with different sources ([@A41446R41]). Our results indicated that none of the isolates were resistant to fluconazole and only one isolate of *C. krusei* showed resistance in a dose dependent manner after 48 hours of incubation. Betts et al., reviewed several literature reports for the effectiveness of caspofungin in neutropenic patients with invasive candidiasis and aspergillosis. They concluded that caspofungin might represent an effective and well-tolerated antifungal drug for such patients ([@A41446R9]). Our results confirmed the previous results that have shown that caspofungin is an effective antifungal drug for candidiasis therapy. Our study shows that 54.7% of isolates were resistant to amphotericin B (\< 8 µg/mL). Furthermore, the most resistant isolates were *C. glabrata* and *C. krusei*. Haddadi et al. in a similar study showed that resistance to amphotericin B was present in *C. albicans*, *C. glabrata* and *C. krusei* ([@A41446R22]).

In summary, during this study we found a marked increase in the incidence of non-species *Candida* (48.2%) among neutropenic patients. In addition, only a few strains were without extracellular enzymes. Finally, the results suggest caspofungin as the first line treatment against *Candida* species among neutropenic patients as well as fluconazole.
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